Cover Image


Rania Chacha, Daniela Petran, Jerome Dauba


In general, metastatic renal cell carcinoma (mRCC) is managed with systemic treatments and cytoreductive nephrectomy is recommended only when it is feasible. Historically, systemic treatment of mRCC was limited to cytokine treatment with interferon (IFN) and interleukin (IL)-2, as chemotherapy was considered to be ineffective in these patients. Bevacizumab in combination with interferon alfa is approved for treatment-nave advanced renal cell carcinoma (RCC) in both the US and Europe. Its objective response rates is 30%. We report a case of a patient who presents a complete response after a nephrectomy and bevacizumab associated to interferon alpha.


bevacizumab; renal cell carcinoma; interferon alfa

Full Text:



Molina AM, Motzer RJ. Current algorithms and prognostic factors in the treatment of metastatic renal cell carcinoma. Clin Genitourin Cancer. 2008, 6( Suppl 1): 7-13

Fisher RI, Rosenberg SA, Fyfe G. Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Can¬cer J Sci Am. 2000, 6(Suppl 1): S55-57

McDermott DF, Regan MM, Clark JI, Flaherty LE, Weiss GR, Logan TF, Kirkwood JM, Gordon MS, Sosman JA, Ernstoff MS, Tretter CP, Urba WJ, Smith JW, Margolin KA, Mier JW, Gollob J A, Dutcher JP, Atkins MB. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol. 2005, 23 (1):133-141

Courtney KD, Choueiri TK. Optimizing recent advances in metastatic renal cell carcinoma. Curr Oncol Rep. 2009, 11 (3): 218-226

Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH. Paclitaxel-carboplatin alone or with beva¬cizumab for non-small-cell lung cancer. N Engl J Med. 2006, 355 (24):2542-2550

Choueiri TK, Vaziri SA, Jaeger E, Elson P, Wood L, Bhalla IP, Small EJ, Weinberg V, Sein N, Simko J, Golshayan AR, Sercia L, Zhou M, Waldman FM, Rini BI, Bukowski RM, Ganapathi R. von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma. J Urol. 2008, 180 (3): 860-865

Sosman J, Puzanov I. Combination targeted therapy in advanced renal cell carcinoma. Cancer. 2009, 115 (10 Suppl):2368-2375

Chowdhury S, Larkin JM, Gore ME. Recent advances in the treatment of renal cell carcinoma and the role of targeted therapies. Eur J Cancer. 2008, 44 (15):2152-2161

Costa LJ, Drabkin HA. Renal cell carcinoma: new developments in molecular biology and potential for targeted therapies. Oncologist. 2007, 12 (12):1404-1415

Rini BI, Halabi S, Rosenberg JE, Stadler WM, Vaena DA, Ou SS, Archer L, Atkins JN, Picus J, Czaykowski P, Dutcher J, Small EJ. Bevacizumab plus interferon alfa compared with interferon alfa monother¬apy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol. 2008, 26 (33):5422-5428

Amato RJ. Chemotherapy for renal cell carcinoma, Semin Oncol. 2000, 27 (2) :177-186

Yagoda A, Petrylak D, Thompson S. Cytotoxic chemotherapy for ad¬vanced renal cell carcinoma. Urol Clin North Am. 1993, 20 (2):303-321

Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011, 61 (4) : 212-236

Chow WH, Devesa SS, Warren JL, Fraumeni JF. Rising incidence of renal cell cancer in the United States. JAMA. 1999, 281 (17):1628-1631

Gupta K, Miller JD, Li JZ, Russell MW, Charbonneau C. Epi¬demiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review. Cancer Treat Rev. 2008, 34 (3):193-205


  • There are currently no refbacks.

AJCC-REP (ISSN 2572-5742)Copyright © 2012-2021. All rights reserved. Published by Ivy Union Publishing, 3204 Valley Rush Dr, Apex, North Carolina 27502, United States